Seeking Alpha

MissionIR's  Instablog

MissionIR
Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
MissionIR
My blog:
MissionIR Blog
  • China Botanic Pharmaceutical, Inc. (CBP) To Be Granted New Invention Patent In China 0 comments
    Aug 29, 2012 2:38 PM | about stocks: CBP

    China Botanic Pharmaceutical recently announced that the State Intellectual Property Office of the People's Republic of China (SIPO) will be granting the company a new invention patent on its comprehensive method to enhance the medicinal value of Schisandra, a key component in its pharmaceutical products. The company expects to receive the patent certificate by October 2012.

    China Botanic filed Patent Application No: 201010119861.3 in February 2010, which was followed by a two-year comprehensive review conducted by the SIPO. Upon grant of the new patent, the company anticipates securing market exclusivity for a period of 20 years.

    Research in China suggests that Schisandra is a wild plant with significant medical and health benefits. Schisandra has been found to prevent liver damage and is an effective sedative for treating insomnia and central nervous system depression. China Botanic's comprehensive method enables it to obtain a number of compounds out of Schisandra, including lignin, polysaccharides, vitamins, and organic acids.

    China Botanic's Chairman and CEO, Mr. Shaoming Li, remarked, "Schisandra is one of the important components for our anti-depression and nervous system regulating products. We look forward to receiving the new patent in October, which will further support our research and development of Schisandra, development of Schisandra-based new medicines and strengthen our ability to leverage the potential of Schisandra. In addition, our continued success in obtaining new patents and our commitment to invest into research, development and talent defines our long-term growth strategy. We believe that in the foreseeable future, our new patent will favorably contribute to our business performance."

    For more information on the company, visit www.renhuang.com

    Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

    Stocks: CBP
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.